Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTU-MultiHIV B clade DNA vaccine in treatment-naive HIV-positive subjects
2005-003071-20Phase 2Completed
- Sponsor
- FIT Biotech Oy
- Start
- Jul 2005
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in human immunodeficiency virus infection (HIV) comparing GTU-MultiHIV B clade DNA vaccine with Placebo (2 arms). Primary endpoint: Cellular immunity mediated by CD8+ T cells. Started Jul 2005; status: completed.
02
Drugs
GTU-MultiHIV B clade vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-003071-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003071-20.